Elevance Health, Inc. Common Stock (ELV)

Health insurance provider Elevance Health (NYSE:ELV) reported Q3 2026 results beating Wall Street’s revenue expectations, but sales were flat year on year at...

Clinical efficiency gains and integrated pharmacy benefits are lengthening the runway for margin expansion beyond 2026.

CEO Boudreaux raised full-year guidance on Medicaid improvements and Carelon momentum.

Elevance Health (NYSE:ELV) raised its 2026 earnings outlook after reporting third-quarter adjusted diluted earnings per share of $6.99, exceeding the company’s expectations as Medicaid, Medicare Advantage and Individual ACA businesses all performed better than anticipated. President and CEO Gail Bo

Health insurance provider Elevance Health (NYSE:ELV) reported revenue ahead of Wall Street’s expectations in Q3 2026, but sales were flat year on year at $50...

Health insurance provider Elevance Health (NYSE:ELV) will be reporting results this Wednesday before market hours. Here’s what investors should know. Elevanc...

Nutex Health and Elevance Health may be underpriced, despite their share growth this year.

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab...

Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financia...

What a time it’s been for Elevance Health. In the past six months alone, the company’s stock price has increased by a massive 47.7%, reaching $414.64 per sha...

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how health insurance provi...

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m...

UnitedHealth Group's Q2 2026 results show improved margins, a lower medical cost ratio, and raised earnings guidance, signaling its turnaround from 2025's steep stock decline is gaining traction.

Peru's $366,050 purchase expands his direct stake to 10,908 shares, now valued at $4.03 million following the stock's 22% one-year gain.

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

Boudreaux's stake now totals ~172,000 directly held shares worth $63.51 million, as Elevance maintains an $80 billion market cap and $5.0 billion in trailing net income.

Elevance Health Inc. (NYSE:ELV) reported strong Q2 results and raised full-year guidance. Analysts have adjusted price targets for ELV stock.

CEO Boudreaux raised full-year guidance after beating Q2 projections.